TY - JOUR ID - 3449 TI - BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management JO - International Journal of Health Policy and Management JA - IJHPM LA - en SN - AU - Rodwin, Victor G. AU - Fabre, Guilhem AU - Ayoub, Rafael F. AD - Robert F. Wagner Graduate School of Public Service, New York University, New York City, NY, USA AD - Université Paul Valéry Montpellier 3, IRIEC EA 740, Montpellier, France AD - Wagner School of Public Service, NewYork University, New York City, NY, USA Y1 - 2018 PY - 2018 VL - 7 IS - 3 SP - 201 EP - 206 KW - Pharma KW - BRIC KW - Health Systems KW - Pharmerging KW - Healthcare KW - Population Health KW - Brazil KW - Russia KW - India KW - China DO - 10.15171/ijhpm.2017.145 N2 - BRIC nations – Brazil, Russia, India, and China – represent 40% of the world’s population, including a growing aging population and middle class with an increasing prevalence of chronic disease. Their healthcare systems increasingly rely on prescription drugs, but they differ from most other healthcare systems because healthcare expenditures in BRIC nations have exhibited the highest revenue growth rates for pharmaceutical multinational corporations (MNCs), Big Pharma. The response of BRIC nations to Big Pharma presents contrasting cases of how governments manage the tensions posed by rising public expectations and limited resources to satisfy them. Understanding these tensions represents an emerging area of research and an important challenge for all those who work in the field of health policy and management (HPAM). UR - https://www.ijhpm.com/article_3449.html L1 - https://www.ijhpm.com/article_3449_a783bb23102ec29f14a05677559d9cc8.pdf ER -